References
- WainwrightCEElbornJSRamseyBWLumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRN Engl J Med2015373322023125981758
- Taylor-CousarJLMunckAMckoneEFTezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delN Engl J Med2017377212013202329099344
- VeitGAvramescuRGChiangANFrom CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutationsMol Biol Cell201627342443326823392
- de BoeckKMunckAWalkerSEfficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutationJ Cyst Fibros201413667468025266159
- SawickiGSMckoneEFPastaDJSustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry dataAm J Respir Crit Care Med2015192783684226132840
- WainwrightCEElbornJSRamseyBWLumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRN Engl J Med2015373322023125981758
- TabcharaniJAChangXBRiordanJRHanrahanJWPhosphorylation-regulated Cl-channel in CHO cells stably expressing the cystic fibrosis geneNature199135263366286311714039
- RichDPAndersonMPGregoryRJExpression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cellsNature199034762913583631699126
- ProtasevichIYangZWangCThermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1Protein Sci201019101917193120687133
- RoweSMVerkmanASCystic fibrosis transmembrane regulator correctors and potentiatorsCold Spring Harb Perspect Med201337115
- RoweSMDainesCRingshausenFCÂ Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic FibrosisN Engl J Med2017377212024203529099333
- MossRBFlumePAElbornJSEfficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialLancet Resp Med201537524533
- RamseyBWDaviesJMcelvaneyNGA CFTR potentiator in patients with cystic fibrosis and the G551D mutationN Engl J Med2011365181663167222047557
- DaviesJCWainwrightCECannyGJEfficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutationAm J Respir Crit Care Med2013187111219122523590265
- HeltsheSLMayer-HamblettNBurnsJLPseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftorClin Infect Dis201560570371225425629
- MckoneEFBorowitzDDrevinekPLong-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)Lancet Respir Med201421190291025311995
- Vertex Press Release2018 Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1055958Accessed October 26, 2018
- MolinskiSVAhmadiSIpWOrkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissueEMBO Mol Med2017991224124328667089
- RabehWMBossardFXuHCorrection of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and functionCell20121481–215016322265408
- OkiyonedaTVeitGDekkersJFMechanism-based corrector combination restores ΔF508-CFTR folding and functionNat Chem Biol20139744445423666117
- MendozaJLSchmidtALiQRequirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequencesCell20121481–216417422265409
- MengXClewsJKargasVWangXFordRCThe cystic fibrosis transmembrane conductance regulator (CFTR) and its stabilityCell Mol Life Sci2017741233827734094
- GentzschMMallMAIon Channel Modulators in Cystic FibrosisChest2018154238339329750923
- GrasemannHCFTR Modulator Therapy for Cystic FibrosisN Engl J Med2017377212085208829099349
- CholonDMGentzschMRecent progress in translational cystic fibrosis research using precision medicine strategiesJ Cyst Fibros2018172SS52S6028986017
- DekkersJFWiegerinckCLde JongeHRA functional CFTR assay using primary cystic fibrosis intestinal organoidsNat Med201319793994523727931
- DekkersJFBerkersGKruisselbrinkECharacterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosisSci Transl Med20168344344ra84
- BrewingtonJJFilbrandtETLarosaFJDetection of CFTR function and modulation in primary human nasal cell spheroidsJ Cyst Fibros2018171263328712885
- GuimbellotJSLeachJMChaudhryIGNasospheroids permit measurements of CFTR-dependent fluid transportJCI Insight2017222pii: 95734
- GraeberSYHugMJSommerburgOIntestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with IvacaftorAm J Respir Crit Care Med2015192101252125526568242
- GraeberSYDopferCNaehrlichLEffects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic FibrosisAm J Respir Crit Care Med2018197111433144229327948
- DekkersJFWiegerinckCLde JongeHRA functional CFTR assay using primary cystic fibrosis intestinal organoidsNat Med201319793994523727931
- GentzschMBoylesSECheluvarajuCPharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial CellsAm J Respir Cell Mol Biol201756556857427983869
- CraneAMKramerPBuiJHTargeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cellsStem Cell Reports20154456957725772471
- TullisEColomboCDaviesJCPreliminary safety and efficacy of triple combination CFTR modulator regiments in CFPoster 777. In: The 31st Annual North American Cystic Fibrosis ConferenceNovember 2–4, 2017Indianapolis, IN
- RatjenFRestoring Airway Surface Liquid in Cystic FibrosisN Engl J Med200635429129316421371
- ZielenskiJGenotype and Phenotype in Cystic FibrosisRespiration200067211713310773783